Precision BioSciences, Inc. (NASDAQ:DTIL) Stock Has Consensus Price Target of $32.25

Precision BioSciences, Inc. (NASDAQ:DTIL) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $32.25.

A number of equities research analysts recently weighed in on DTIL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precision BioSciences in a report on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Finally, Wall Street Zen lowered shares of Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th.

Institutional Trading of Precision BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Engineers Gate Manager LP acquired a new stake in Precision BioSciences during the 2nd quarter valued at approximately $164,000. Squarepoint Ops LLC increased its holdings in Precision BioSciences by 212.7% in the second quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock valued at $1,078,000 after buying an additional 93,258 shares during the last quarter. Corient Private Wealth LP raised its stake in Precision BioSciences by 70.4% during the second quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock valued at $1,926,000 after buying an additional 101,206 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Precision BioSciences in the 2nd quarter worth approximately $467,000. Finally, Bank of America Corp DE increased its holdings in shares of Precision BioSciences by 167.6% in the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock valued at $151,000 after acquiring an additional 17,172 shares during the last quarter. 37.99% of the stock is owned by hedge funds and other institutional investors.

Precision BioSciences Stock Down 6.5%

Precision BioSciences stock opened at $5.77 on Monday. The stock’s 50 day moving average price is $7.09 and its 200 day moving average price is $7.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 12.82 and a quick ratio of 12.82. Precision BioSciences has a one year low of $3.53 and a one year high of $9.62.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. Research analysts forecast that Precision BioSciences will post -3.33 earnings per share for the current fiscal year.

About Precision BioSciences

Precision BioSciences, Inc is a biotechnology company developing gene-editing therapies for serious diseases. The company’s work is based primarily on its proprietary ARCUS platform, which uses engineered nucleases designed to make precise changes to DNA inside the body.

Precision BioSciences is focused on in vivo gene editing programs addressing conditions including chronic hepatitis B, Duchenne muscular dystrophy and alpha-1 antitrypsin deficiency. Its development efforts are intended to remove, insert or repair genetic material and potentially provide durable treatments after a single administration.

Founded in 2006 and headquartered in Durham, North Carolina, the company has also pursued cell therapy programs and strategic collaborations to apply its gene-editing technology to additional therapeutic areas.